Neupogen

This page shows the latest Neupogen news and features for those working in and with pharma, biotech and healthcare.

Novartis doubles down on biosimilars with Biocon alliance

Previous launches have included its Glatopa version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate) and Zarxio, a variant of Amgen’s Neupogen (filgrastim).

Latest news

Novartis takes biosimilar delay complaint to Supreme Court

Novartis is appealing an earlier ruling which ordered the company to delay launch of Zarxio, its version of Amgen's white blood cell stimulator Neupogen (filgrastim) and the first biosimilar to
Novartis claims first place for its biosimilar Enbrel in US

biosimilars business after the company got a green light for its Zarxio copy of Amgen's neutropenia therapy Neupogen (filgrastim).
Novartis gets FDA panel backing for biosimilar Enbrel

The GP2015 recommendation also puts Novartis on course for a second biosimilar approval in the US after its Zarxio product, a copy of Amgen's white blood cell stimulator Neupogen (filgrastim)
Sandoz files for approval of Neulasta biosimilar in Europe

The generic drug specialist - which also sells a biosimilar version of Amgen's short-acting GCSF product Neupogen (filgrastim) - said the Neulasta filing means it is now halfway to its objective
FDA panel recommends first biosimilar antibody for approval

The drug is also only the second biosimilar to be approved in the US after Novartis/Sandoz' Zarxio (filgrastim-sndz), which is a copy of Amgen's white cell stimulator Neupogen

More from news
Approximately 8 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Customer experience rules the digital age

Establishing an effective customer journey
Embracing digital disruption in pharma

LEO Innovation Lab and some of its successes to date
Biosimilars - the same, but different?

Neupogen (filgrastim).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Biosimilars: Getting the flock to market

Biosimilars: Getting the flock to market. The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd. Biosimilars have now been with us for over 10 years. In case you haven't been paying

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Programme Executive: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Scientific Director: Great salary and bebefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editorial Director – Medical Education – Oxford: Negotiable

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Medical Writer: Great salary and benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...